Protein phosphorylation is an important component of vasopressin signaling in the renal collecting duct, but the database of known phosphoproteins is incomplete. We used tandem mass spectrometry to identify vasopressin-regulated phosphorylation events in isolated rat inner medullary collecting duct (IMCD) suspensions. Using multiple search algorithms to identify the phosphopeptides from spectral data, we expanded the size of the existing collecting duct phosphoproteome database from 367 to 1187 entries. Label-free quantification in vasopressin-and vehicle-treated samples detected a significant change in the phosphorylation of 29 of 530 quantified phosphopeptides. The targets include important structural, regulatory, and transporter proteins. The vasopressin-regulated sites included two known sites (Ser-486 and Ser-499) present in the urea channel UT-A1 and one previously unknown site (Ser-84) on vasopressin-sensitive urea channels UT-A1 and UT-A3. In vitro assays using synthetic peptides showed that purified protein kinase A (PKA) could phosphorylate all three sites, and immunoblotting confirmed the PKA dependence of Ser-84 and Ser-486 phosphorylation. These results expand the known list of collecting duct phosphoproteins and highlight the utility of targeted phosphoproteomic approaches.
Vasopressin plays a central role in collecting duct physiology. Signaling through the V2 receptor results in an increase of cAMP levels and causes activation of protein kinase A (PKA). 1, 2 In addition, over 200 other serine/threonine protein kinases are expressed in native collecting duct cells, 3 and some of these have been shown to play important roles in the response to vasopressin. 4 -10 Vasopressin signaling is important not only for regulation of water transport through aquaporins 11 but also for regulation of urea 12 and sodium transport. 13, 14 Vasopressin also regulates long-term gene expression of collecting duct proteins, such as aquaporins. 15, 16 Because protein phosphorylation plays a central role in vasopressin signaling, the identification and quantification of phosphorylated proteins in response to vasopressin are essential to understanding the mechanism of action of this hormone in collecting duct.
In a previous study, 17 we used tandem mass spectrometry (LC-MS/MS)-based quantitative phosphoproteomics to partially annotate the phosphoproteome of rat inner medullary collecting duct (IMCD). We subsequently quantified the differential phosphorylation of four serine residues (Ser-256, Ser-261, Ser-264, and Ser-269) in the C-terminal tail of rat aquaporin-2 (AQP2) in response to short-term exposure to the vasopressin analog dDAVP. 17, 18 We also found a number of phosphor-ylation sites on the vasopressin-sensitive urea channel, UT-A. 17 However, because of the limited sensitivity of the experimental approach, we were unable to quantify changes in phosphorylation at these sites in UT-A, despite evidence for such sites on the basis of previous studies. 19, 20 One of the primary aims of this study was to increase the sensitivity of our MS-based workflow to annotate a larger portion of the IMCD phosphoproteome. This was accomplished in three ways: (1) by implementing an effective, chromatography-based stratification technique for our peptide samples, (2) by using a higher resolution mass spectrometer, and (3) by using multiple proteomic search algorithms to process the MS data. Using these combined approaches, we increased coverage of the IMCD phosphoproteome by approximately 3-fold compared with the previous study. 17 In addition, we present largescale phosphoproteomic data quantifying the effect of vasopressin on phosphorylation of IMCD proteins. Last, we identify and quantify six phosphorylation sites on the vasopressin-sensitive urea channel (isoforms A1 and A3) and demonstrate that three of these sites undergo large increases in phosphorylation in response to short-term dDAVP treatment.
RESULTS

Phosphoproteomic Profiling of IMCD
Our previous study using an LC-MS/MS "shotgun" approach identified 223 unique phosphoproteins in native IMCD cells. 17 One of the aims of this study was to expand the size of the identified collecting duct phosphoproteome by adding methods that would increase overall sensitivity; viz., using sample fractionation via strong cation exchange (SCX) and employing multiple MS search algorithms. SCX was performed on a single dDAVP-treated IMCD sample ( Figure 1A ) as described in "Concise Methods," followed by phosphopeptide enrichment via immobilized metal affinity chromatography (IMAC). Samples representing 24 SCX fractions were analyzed on a Thermo LTQ mass spectrometer, and the resulting spectra were searched using three different search algorithms: SEQUEST, InsPecT, and OMSSA. Figure 2 shows a Venn diagram of unique phosphopeptides identified from each of the three search algorithms. All datasets were filtered for a Ͻ2% falsediscovery rate on the basis of target-decoy analysis. 21 Combined total 2707
Figure 2. Venn diagram shows the number of unique phosphopeptide identifications that resulted from each of three search algorithms (SEQUEST, InsPecT, and OMSSA). A false-discovery rate stringency of Ͻ2% was used for each of the searches.
ping regions consist of phosphopeptides that were identified by more than one search algorithm and indicate a match not only of the phosphopeptide primary amino acid sequence but also for the exact site(s) of phosphorylation. 
Verification of IMCD Response to dDAVP
After profiling the dDAVP-treated IMCD phosphoproteome, we performed large-scale profiling experiments on paired vehicle and dDAVP-treated IMCD samples to determine which phosphoproteins were regulated by vasopressin. Phosphorylation on Ser-256 of AQP2 occurred in response to short-term vasopressin exposure, 17 and immunoblotting with a phosphospecific antibody was used to verify the expected increase in Ser(p)-256 abundance in vasopressin-treated samples. Figure 3 shows that dDAVP increased the amount of Ser(p)-256-AQP2 compared with control samples (bands at 29 and 37 kDa). Total protein abundance of AQP2 does not change with dDAVP treatment, as shown by Hoffert et al. 18 
Large-Scale Quantitative Phosphoproteomics Reveals Potential Downstream Targets of Vasopressin Signaling
We isolated IMCD suspensions and prepared five paired control and dDAVPtreated samples all from different rats. Samples were digested with trypsin; phosphopeptide enrichment was performed using IMAC; and the samples were analyzed on the LTQ-Orbitrap MS platform using collision-induced dissociation (CID) fragmentation ( Figure 1B ). All 10 samples were searched with SE-QUEST (false-discovery rate Ͻ2%), and relative quantification was performed using QUOIL. 22 A total of 530 unique phosphopeptides from 278 proteins were quantified ( Figure  4 ). For statistical analysis, values were converted to log 2 of the ratio (D/C), where D and C refer to the normalized areas of the extracted peptide ion chromatograms under dDAVP-treated and control conditions, respectively. Brackets in Figure 4 indicate the subset of 54 phosphopeptides with log 2 (D/C) values either greater than 0.58 or less than Ϫ0.58. Of these 54 phosphopeptides, 29 represented phosphopeptides with statistically significant (P Ͻ 0.05) changes in abundance between the five paired control and dDAVP-treated IMCD tubules. These phosphopeptides are shown in Table 1 
Regulation of ␤-Catenin Phosphorylation by dDAVP
One of the phosphorylation sites that increased in response to dDAVP was Ser-552 of ␤-catenin (Table 1 , part B). Because ␤-catenin has been proposed to play a role in regulation of aquaporin-2, 23 we investigated this response further using a phosphospecific antibody. Figure 5A shows an immunoblot performed on protein isolates from the same five pairs of animals used in our large-scale quantitation experiment. The blot was probed with an antibody recognizing Ser(p)-552-␤-catenin. As shown in Figure 5A , Ser(p)-552-␤-catenin was increased 3- BASIC RESEARCH www.jasn.org treatment does not (P Ͼ 0.40) increase total protein abundance ( Figure 5A , bottom). Thus, we were able to show convergent results for increased ␤-catenin phosphorylation on Ser-552 in response to dDAVP treatment using both LC-MS/MS and immunoblotting.
To address whether a similar change in ␤-catenin phosphorylation occurs in the inner medulla of intact kidney, Brattleboro rats were injected intramuscularly with dDAVP or vehicle, and in 45 minutes, the whole inner medulla was isolated for immunoblot analysis. As shown in Figure 5B , Ser(p)-552-␤-catenin was increased nearly 2-fold in response to dDAVP (band densities: vehicle, 10.9 Ϯ 1.1; dDAVP, 20.1 Ϯ 2.6; P Ͻ 0.05). Before examining the effect of short-term dDAVP treatment on UT-A phosphorylation, it was necessary to establish that total UT-A protein abundance does not change as a result of short-term dDAVP treatment, and thus was not contributing to changes in abundance of the UT-A phosphopeptides. The immunoblot in Figure 6 was probed with an antibody recognizing total UT-A1. 24 The 97-and 117-kD bands represent UT-A1. There was no significant difference between control and treated samples (P ϭ 0.11). The same immunoblot was also probed with a phosphospecific antibody recognizing Ser(p)-256 on AQP2 to verify the responsiveness of IMCD tubules to dDAVP stimulation.
From our SCX profiling data, we identified phosphorylation of the vasopressin-sensitive urea channel (isoforms A1 and A3) on Ser-10, Ser-62, Ser-63, Ser-84, and Ser-486 (http:// dir.nhlbi.nih.gov/papers/lkem/mpkccdprot/). Of these five sites, Ser-10 and Ser-84 have not been previously reported. Ser-486 was identified by Hoffert et al. 17 using a similar approach and was subsequently found to be functionally important for urea transport activity by Blount et al. 20 The same study also demonstrated the importance of phosphorylation at Ser-499 for the transport function of UT-A1. 20 For this study, a trypsin digest could not be used to identify the peptide containing Ser-499, because the resulting peptide was too short for LC-MS/MS detection. Alternatively, sample digestion with chymotrypsin was predicted to produce a peptide of suitable length. However, attempts to identify the Ser-499-containing chymotryptic peptide were precluded by poor fragmentation of the parent ion using CID as the fragmentation technique. Therefore, we used an alternative fragmentation technique, electron transfer dissociation (ETD), to successfully identify the chymotryptic peptide containing Ser-499 ( Figure 7C ), and CID was used for the remaining sites (Ser-10, Ser-62/63, Ser-84, and Ser-486).
On the basis of phosphorylation sites identified from our profiling data and evidence showing that Ser-499 is functionally important for urea transport, 20 we used targeted selection of precursor ion masses, so-called targeted ion selection (TIS) ( Figure 1C) , to quantify changes in phosphorylation in response to dDAVP for each of the sites. dDAVP treatment resulted in no change in phosphorylation at Ser-10 (Supplementary Figure 1 ) or phosphorylation at both Ser-62 and Ser-63 (Supplementary Figure 2) . However, phosphorylation at Ser-84, Ser-486, and Ser-499 increased significantly (P Ͻ 0.02) in response to dDAVP. Figure 7 shows representative reconstructed ion chromatograms for UT-A1 contains several putative PKA phosphorylation motifs, [25] [26] [27] including Ser-84, Ser-486, and Ser-499. To determine whether PKA can, in fact, phosphorylate these three sites, we performed in vitro assays using purified PKA catalytic subunit and synthetic UT-A peptides as substrates. Figure 8A shows phosphorylation on the C-terminal tail of aquaporin-2 on Ser-256, which served as a positive control. In addition, PKA also was able to phosphorylate peptides containing Ser-486, Ser-84, and Ser-499 sites on UT-A1 ( Figure 8 , B, C, and D, respectively). To test whether PKA regulates phosphorylation of UT-A1 and UT-A3 in vivo, isolated rat IMCD samples were incubated with dDAVP in the presence or absence of 10 M PKA inhibitor H89, followed by immunoblotting with newly generated antibodies that recognize phosphorylated UT-A1 and UT-A3 at Ser-84, and phosphorylated UT-A1 at Ser-486 ( Figure 9A ). Phosphorylation at both Ser-84 and Ser-486 was significantly reduced in the presence of H89, suggesting that PKA may directly or indirectly regulate phosphorylation at these sites in response to short-term dDAVP treatment ( Figure 9 , A, C, D, and E). Inhibition of Ser(p)-256-AQP2 was used as a positive control to demonstrate that the H89 drug was working ( Figure 9 , A and B). A recent study has also implicated the MEK-ERK pathway in regulating UT-A phosphorylation in response to forskolin in rat IMCD. 28 To test whether extracellular signal-regulated kinase (ERK) mitogen-activated protein (MAP) kinase is involved in regulating UT-A phosphorylation, isolated rat IMCD samples were incubated with dDAVP in the presence or absence of 10 M MEK1/2 (map kinase kinase 1 and 2) inhibitor U0126. Immunoblotting for phosphorylated ERK (pERK) demonstrated that dDAVP treatment did not increase ERK phosphorylation and that U0126 significantly blocked ERK phosphorylation in both control and dDAVP-treated samples ( Figure 9 , A and F). U0126 also produced a slight but significant reduction in UT-A1 phosphorylated at Ser-84 in dDAVPtreated samples ( Figure 9C ). However, inhibition of the ERK pathway failed to significantly affect the level of AQP2 phosphorylated at Ser-256, UT-A3 phosphorylated at Ser-84, and UT-A1 phosphorylated at Ser-486 ( Figure 9 , B, D, and E, respectively).
DISCUSSION
The new advances in proteomic methodologies used here allow an unbiased, large-scale, discovery-based approach for the study of cell signaling. Here, we have applied these methodologies to vasopressin signaling in the renal collecting duct. Because water and urea transport are known to be vasopressinregulated, we decided to emphasize our data focusing on phosphorylation of aquaporins and urea channels. However, a large-scale LC-MS/MS approach also allows unanticipated observations to be made regarding other parts of the signaling network. Here, we discuss examples of both types of observations: (1) regulated phosphorylation of UT-A urea channel isoforms and (2) regulation of ␤-catenin phosphorylation by vasopressin.
Our data identify and quantify multiple vasopressin-regulated phosphorylation sites on the urea channel (UT-A1 and UT-A3). A schematic of these sites and their relative locations on UT-A1 and UT-A3 is summarized in Figure 10 . A previous study 17 identified four phosphorylation sites (Ser-35, Ser-62, Ser-63, and Ser-486). In this study, we confirm previously identified sites and also report two previously unknown phosphorylation sites (Ser-10 and Ser-84). Of the sites reported in this study, we demonstrate that three (Ser-84, Ser-486, and Ser-499) are strongly regulated by vasopressin both by LC-MS/MS ( Figure 6 ) and immunoblot ( Figure 9 ) analysis. In a previous study using transfected LLC-PK 1 cells, Blount et al. 20 showed that S486A and S499A mutants each had reduced 32 P incorporation into UT-A1 as well as attenuated urea flux in response to forskolin treatment. The importance of these two sites was highlighted by the fact that the S486A/S499A double mutants did not show any significant urea flux increase in response to forskolin. Because of the lack of site specificity of the 32 P labeling technique employed in the study, quantitative conclusions concerning phosphorylation of these sites could not be made. In our study, we show that phosphorylation at each of these two sites increased approximately 4-fold with dDAVP exposure for 30 minutes. Because surrounding amino acid sequences from both sites are compatible with PKA as the kinase involved, 27 we performed in vitro assays that showed PKA can phosphorylate both Ser-486 and Ser-499 (Figure 8 ). However, several other kinases have specificities similar to PKA, 29 and consequently the kinase responsible for in vivo phosphorylation of these sites cannot be specified with certainty.
Our study also demonstrated a previously unknown site (Ser-84) on the N-terminal tail of the urea channel that is phosphorylated in response to dDAVP. Ser-84 is contained within a putative PKA motif, 27 and an in vitro assay showed that PKA can phosphorylate this site (Figure 8 ). This site is present in both UT-A1 and UT-A3, and it is the only regulated site shared by both isoforms. The use of newly developed phosphospecific UT-A antibodies definitively showed that phosphorylation of this site is indeed increased by dDAVP treatment in both isoforms.
Further evidence supporting a role for PKA in regulating phosphorylation of collecting duct urea channels was found by using the inhibitor H89, which nearly completely blocked phosphorylation at both Ser-84 and Ser-486. Results from U0126 inhibitor studies suggested that the MEK-ERK pathway may also play a role in regulating phosphorylation of UT-A1 at Ser-84 but not at Ser-486. However, U0126 did not block the ability of dDAVP to increase phosphorylation of UT-A1 at either site or UT-A3 at Ser-84. Furthermore, neither Ser-84 nor Ser-486 is part of a proline-directed consensus motif, which would be compatible with direct phosphorylation by a MAP kinase. 27 Regarding the evolutionary conservation of these sites, Ser-499 is highly conserved across rat, mouse, horse, cow, and human UT-A1. Ser-486 was also conserved in all of these species except for cow, where it is an asparagine residue. Ser-84 was less conserved, being replaced by aspartic acid in human and arginine in horse. The aspartic acid in human has the same charge (Ϫ1) as a phosphorylated serine and could conceivably represent a constitutively activated form.
Other UT-A sites that were quantified but were shown to not be regulated by vasopressin were Ser-10, Ser-62, and Ser-63. None of these sites have neighboring amino acids suggestive of a PKA or any other basophilic motif. However, these sites may still be important for other regulatory pathways.
In addition to UT-A, our study successfully quantified changes in site-specific phosphorylation of multiple other proteins, including Ser-552 on ␤-catenin (Table 1 and Figure 5 ). Ser-552 on ␤-catenin was found to undergo a large increase BASIC RESEARCH www.jasn.org in phosphorylation in response to vasopressin, both in vitro ( Figure 5A ) and in vivo ( Figure 5B ). ␤-Catenin is a wellstudied cytoplasmic protein that has two general roles in cells: (1) a structural role in cadherin-mediated cell adhesion and (2) a signaling role as a transcriptional coregulator. 30 It is involved in the highly conserved canonical Wnt signaling pathway. Although involvement of ␤-catenin in the embryonic development of the collecting duct has been well studied, [31] [32] [33] there is only indirect evidence regarding its relationship to vasopressin signaling in the mature collecting duct. 23 The amino acid sequence surrounding Ser-552 of ␤-catenin (…QRRTS 552 MGGT…) is consistent with a PKA motif. 27 Through 32 P labeling and site-directed mutagenesis, it has been shown previously that PKA can phosphorylate Ser-552. 34 Subsequent studies demonstrated that phosphorylation of Ser-552 by PKA can facilitate the interaction between ␤-catenin and T cell factor, a transcription factor that up-regulates gene expression related to cell growth. 35 Given the fact that we have shown vasopressin causes increased phosphorylation of Ser-552 on ␤-catenin in the collecting duct, an important future direction will be to elucidate whether similar interactions among vasopressin, ␤-catenin, and expression of growth-promoting genes are also relevant for the collecting duct.
Gene Ontology analysis and Conserved Domain analysis of proteins identified in Table 1 did not point to any single category of proteins that are regulated by dDAVP (Supplementary Data). However, several proteins whose phosphorylation is increased have potential roles in regulation of aquaporin-2 and/or UT-A isoforms. For example, the PCTAIRE-3 protein kinase was strongly phosphorylated at Ser-66, a putative PKA site, in response to dDAVP. This kinase is differentially expressed in IMCD versus non-collecting duct cells 3 and is thought to be involved in membrane trafficking. 36 In addition, plexin domain containing-2 is also strongly phosphorylated at a putative PKA site (Ser-507). This protein has been shown to bind cortactin, which is an important regulator of actin polymerization at cell adhesion sites. 37 In contrast, several phosphorylation sites were found to be strongly down-regulated in proteins that have relevance to aquaporin-2 and/or UT-A regulation. For example, septin-9 phosphorylation was strongly down-regulated at Ser-67, a putative MAP kinase site. Septins are polymeric GTP-binding proteins that associate with cell membranes as well as the actin and microtubule cytoskeletons. 38 Furthermore, a protein called ArfGAP with FG repeats 1 also undergoes a marked decrease in phosphorylation in response to dDAVP at several proline-directed sites. This protein is believed to be involved in vesicle docking and fusion in acrosome formation in spermatozoa 39 and could play a role in regulation of membrane trafficking in the collecting duct. Finally, epsin-3 underwent a marked decrease in phosphorylation at Thr-361 a putative MAP kinase site. This protein functions as a ubiquitin-dependent clathrin adaptor and may be involved in regulation of membrane trafficking in the collecting duct. 40 
CONCISE METHODS
IMCD Isolation
Sprague-Dawley rats were obtained between 1 and 3 months of age (Animal Care and Use Committee protocol number H-0110). Furosemide was injected into the rats (intraperitoneally, 0.5 mg) 30 minutes before euthanization. Both kidneys were removed, and the inner medullas were dissected out. IMCD isolation was performed using a modified version of previously outlined methods. 41, 42 Inner medullas were minced with a razorblade and digested for approximately 75 minutes at 37°C in an enzyme solution containing 3 mg/ml collagenase B and 3 mg/ml hyaluronidase dissolved in sucrose buffer (250 mM sucrose and 10 mM triethanolamine, pH 7.6). After enzyme digestion, a low-speed spin (70 ϫ g, 20 seconds) was used to pellet IMCD cells. Cells were rinsed twice with sucrose buffer and once with bicarbonate buffer (118 mM NaCl, 25 mM NaHCO 3 , 5.5 mM glucose, 5 mM KCl, 4 mM Na 2 HPO 4 , 2 mM CaCl 2 , and 1.2 mM MgSO 4 , pH 7.4). Cells were resuspended in bicarbonate buffer, and samples were treated with either 1 nM dDAVP or vehicle for 30 minutes at 37°C in a pH-and temperature-controlled chamber. For studies using H89 and U0126, the drug was added for a 10-minute preincubation period followed by addition of 1 nM dDAVP for 20 minutes. Data in the phosphoproteome profiling experiment were derived only from a dDAVP-treated sample without a vehicle-treated control ( Figure 1A) .
Reduction, Alkylation, and In-Solution Protease Digestion
After dDAVP treatment, IMCD tubules were resuspended in lysis buffer (8 M urea, 75 mM NaCl, 50 mM Tris-HCl, with protease and phosphatase inhibitors). Cells were sonicated with 0.5-second pulses for 30 cycles followed by centrifugation at 10,000 ϫ g for 10 minutes. Protein concentration in the supernatants was determined using the BCA protein assay (Pierce, Rockford, IL). Approximately 1 mg of protein was used for large-scale phosphoproteome profiling, whereas 500 g was used for quantitative studies. Samples were reduced for 1 hour with 10 mM dithiothreitol, followed by alkylation with 40 mM iodoacetamide for 1 hour in the dark. 40 mM dithiothreitol was added to quench unreacted iodoacetamide. Samples were diluted to a urea concentration of Ͻ1 M and digested with trypsin (Promega, Madison, WI) overnight at 37°C in 50 mM ammonium bicarbonate. For samples digested with chymotrypsin (Roche, Penzberg, Germany), the reaction was performed for 16 hours at 25°C in 100 mM Tris-HCl and 5 mM CaCl 2 .
Desalting, Phosphopeptide Enrichment, and Sample Fractionation
After protease digestion, peptide samples were desalted using a 1-cc HLB cartridge (Waters, Milford, MA) and dried by SpeedVac. The dried peptides were resuspended in 300 l of solvent A (5 mM KH 2 PO 4 , 25% acetonitrile (ACN), pH 2.7) and injected onto a PolySulfoethyl A SCX column (4.6-mm inner diameter ϫ 20-cm length, 5-m particle size, 300-Å pore size). SCX chromatography was carried out on an Agilent HP1100 system at 1 ml/min flow rate using the following gradient: 0% solvent B for 2 minutes; 0 to 20% solvent B for 40 minutes; 20% to 100% solvent B for 5 minutes; and 100% solvent B held for 5 minutes (solvent B: 5 mM KH 2 PO 4 , 25% ACN, and 350 mM KCl, pH 2.7). UV absorbance at 214 nm was monitored while fractions were collected at 1.5-ml intervals and dried down by SpeedVac. All 24 fractions were desalted on 1-cc HLB cartridges (Waters) before phosphopeptide enrichment. SCX was not used in other analysis methods, such as TIS or label-free LC-MS/MS quantitation. Phosphopeptide enrichment was performed as described 17 using immobilized metal affinity chromatography (IMAC) with a Ga 3ϩ matrix (Phosphopeptide Isolation Kit; Pierce). Before analysis by MS/MS, samples were desalted using C18 Ziptips (Millipore) and resuspended in 0.1% formic acid.
LC-MS/MS Analysis on Linear Trap Quadrupole
An Agilent 1100 nanoflow LC system (Palo Alto, CA) connected to a Finnigan linear trap quadrupole (LTQ) mass spectrometer (Thermo Electron, San Jose, CA) was used for LC-MS/MS analysis. Peptide trapping was performed at a flow rate of 2 l/min. Peptides were eluted onto a reversed-phase PicoFrit column (New Objective, Woburn, MA), and separation was performed using a linear ACN gradient (0 to 60%) in 0.1% formic acid. Peptides were introduced into the LTQ mass spectrometer using a nanospray ion source. The spray voltage was set to 2 kV and collision energy to 35%. Datadependent acquisition mode (dynamic exclusion enabled) was used for profiling experiments. Survey MS1 scans were followed by five MS2 scans. TIS was performed with predetermined masses entered into an inclusion list (dynamic exclusion disabled).
LC-MS/MS Analysis on LTQ-Orbitrap
All dried fractions were analyzed on an LTQ-Orbitrap (ThermoFisher Scientific LLC) interfaced with an Eksigent nano-LC 1D plus system (Eksigent Technologies LLC, Dublin, CA) using CID fragmentation. Briefly, samples were loaded onto an Agilent Zorbax 300SB-C18 trap column (0.3-mm inner diameter ϫ 5-mm length, 5-m particle size) at a flow rate of 5 l/min for 10 minutes. Reversed-phase C 18 chromatographic separation of peptides was carried out on a prepacked PicoFrit column (75-m inner diameter ϫ 10-cm length; New Objective) at 300 nl/min using the following gradient: 2% to 5% solvent B for 5 minutes; 5% to 45% solvent B for 60 minutes; 45% to 50% solvent B for 5 minutes; and 50% to 95% solvent B for 5 minutes (solvent A: 0.1% formic acid in 98% water, 2% ACN; solvent B: 0.1% formic acid in 100% ACN). LTQ-Orbitrap settings were as follows: spray voltage 1.5 kV; full MS mass range: m/z 300 to 2000; and MS/MS mass range: m/z 100 to 2000. The LTQ-Orbitrap was operated in a data-dependent mode; i.e., one MS1 high resolution scan for precursor ions followed by three data-dependent MS2 scans for precursor ions above a threshold ion count of 2000 with collision energy of 35%. In some cases, parent ion masses were entered into an inclusion list for TIS experiments. MS3 scans were automatically triggered on the basis of the observation of neutral loss peaks of phosphoric acids from precursor ions in MS2 scans that met a threshold criterion of 500 counts.
ETD and Decision Tree-Driven Tandem MS/MS
ETD parameters were tuned using bovine growth hormone-releasing receptor (Sigma G0644). The reaction time was optimized at 85 milliseconds (with an AGC target for fluoranthene radical anion of 300,000). Online mass spectrometric experiments were performed by MS1 analysis in the Orbitrap at 30,000 resolution followed by five data-dependent MS/MS events with product ion analysis performed in the LTQ. The precursor ions selected for MS/MS were determined by intensity within MS1 (Ն1000 counts) followed by dynamic exclusion (30 seconds or a peak list of 500) and charge state inclusion (ions with two or more charges). The form of MS/MS activation was either ETD-only, CID-only, or decision tree-based selection. 43 When using the decision tree-based selection, the dissociation method for every MS/MS event was determined in real time in an automated fashion on the basis of the precursor z and m/z. This feature was fully incorporated into the LTQ Tune 2.5.5 instrument control software (default setting).
Data Searching, Scoring, Quantification, and Bioinformatics Searches were performed using the latest version of the rat RefSeq database (National Center for Biotechnology Information), with concatenated forward and reversed sequences to allow for target-decoy analysis. The database also contained sequences for common MS contaminants, such as human keratin and porcine trypsin. Data from the phosphoproteome profiling experiment were searched with SE-QUEST, 44 InsPecT, 45, 46 and OMSSA. 47 InsPecT and OMSSA searches used the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health, Bethesda, MD (http://biowulf.nih.gov). All of the other data were searched using SEQUEST only. Filtering and determination of false-discovery rate were done using methods described previously. 48, 49 All datasets were filtered for a false-discovery rate of Ͻ2%. Phosphorylation site localization was performed using Ascore 50 and PhosphoScore. 51 Label-free phosphopeptide quantification was performed using QUOIL. 22 Gene Ontology and Conserved Domain Database analyses were performed using in-house software.
Brattleboro Rats
Brattleboro rats (Animal Care and Use Committee protocol number H-0110) were injected with dDAVP (2 nmol dissolved in saline) or BASIC RESEARCH www.jasn.org vehicle intramuscularly and then euthanized after 45 minutes. Inner medullas were dissected, homogenized, and solubilized in Laemmli buffer as described previously. 9 Antibodies Affinity-purified rabbit polyclonal antibodies against rat Ser(p)-256-AQP2 52 and total UT-A1 (L448) 24 have been previously described. Phosphospecific antibodies were generated against sequences surrounding residues Ser-84 and Ser-486 of rat UT-A1 (PhosphoSolutions, Aurora, CO). Specificity of these antibodies was established by dotblot (data not shown) and immunoblot. A phosphospecific antibody recognizing Ser(p)-552-␤-catenin was obtained from Cell Signaling Technology (product no. 9566; Danvers, MA).
Immunoblot Analysis
Immunoblotting was used to assess the response of AQP2 and UT-A1 to dDAVP treatment and was carried out using previously described methods. 17, 48 In vitro Phosphorylation Assay
We performed an in vitro assay to determine whether particular serine residues contained within in silico-predicted PKA phosphorylation consensus motifs in UT-A1 could be phosphorylated by PKA. We obtained synthetic peptides corresponding to sequences surrounding the S84, S486, and S499 residues of UT-A1 (AnaSpec, San Jose, CA). We used a peptide with the amino acid sequence of the C-terminal tail of AQP2 18 as a positive control. We incubated a total of 5 g of each peptide with 1ϫ kinase buffer and 200 M ATP (Cell Signaling Technology, Beverly, MA) in the presence or absence of PKA C-␣ kinase (Cell Signaling Technology, Beverly, MA) for 1 hour at 30°C. After incubation, the reaction mixtures were digested overnight with either trypsin at 37°C or chymotrypsin (for Ser-84 peptide) at 25°C. Samples were then desalted, resuspended in 0.1% formic acid, and analyzed on an LTQ mass spectrometer (Thermo Electron).
